Cargando…

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Fang, Wenfeng, Jin, Haoxuan, Zhou, Huaqiang, Hong, Shaodong, Ma, Yuxiang, Zhang, Yaxiong, Su, Xiaofan, Chen, Longyun, Yang, Yunpeng, Xu, Shengqiang, Liao, Yuwei, He, Yuming, Zhao, Hongyun, Huang, Yan, Gao, Zhibo, Zhang, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901210/ https://www.ncbi.nlm.nih.gov/pubmed/33622313 http://dx.doi.org/10.1186/s12943-021-01331-9

Ejemplares similares

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2021)

Incidence and risk factors of second primary cancer after the initial primary human papillomavirus related neoplasms
por: Shen, Jiayi, et al.
Publicado: (2020)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
por: Zhao, Shen, et al.
Publicado: (2020)

Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes?
por: Zhang, Yaxiong, et al.
Publicado: (2019)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
por: Ali, Wael A. S., et al.
Publicado: (2023)

MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
por: Fang, Wenfeng, et al.
Publicado: (2020)

Impact of prior cancer history on the overall survival of younger patients with lung cancer
por: Liu, Jiaqing, et al.
Publicado: (2020)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Zhonghan, et al.
Publicado: (2020)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Docosapentaenoic acid and lung cancer risk: A Mendelian randomization study
por: Liu, Jiaqing, et al.
Publicado: (2019)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019
por: Liu, Jiaqing, et al.
Publicado: (2020)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
por: Zhang, Xuanye, et al.
Publicado: (2019)

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
por: Fang, Wenfeng, et al.
Publicado: (2014)

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
por: Sheng, Jin, et al.
Publicado: (2015)

Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses
por: Liang, Wenhua, et al.
Publicado: (2014)

Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma
por: Ran, Xia, et al.
Publicado: (2020)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015)

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Tang, Yanna, et al.
Publicado: (2015)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer
por: Zhou, Ting, et al.
Publicado: (2015)

Intratumor graph neural network recovers hidden prognostic value of multi-biomarker spatial heterogeneity
por: Qiu, Lida, et al.
Publicado: (2022)

A modifiable risk factors atlas of lung cancer: A Mendelian randomization study
por: Shen, Jiayi, et al.
Publicado: (2021)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

Evolutionary Dynamics of Intratumor Heterogeneity
por: Iwasa, Yoh, et al.
Publicado: (2011)

Targeting the intratumor heterogeneity in PMBL
por: Ritz, Olga, et al.
Publicado: (2014)

Intratumor and Intertumor Heterogeneity in Melanoma
por: Grzywa, Tomasz M., et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Intratumoral Heterogeneity in Lung Cancer
por: Lv, Xiaodi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_daolop2ut2oslaj6kvsseq8t4s